Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
211
Recruiting, any sponsor type, condition "systemic lupus erythematosus"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting211
- Completed368
211 trials
Showing 1 to 25, recently updated first.
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05835310 · 100 participants (planned) · Start Mar 14, 2024 · Primary completion Oct 5, 2028
Drug: Anifrolumab; Placebo · For: Systemic Lupus Erythematosus
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 111 sites in all
AbbVieAbbVie (ABBV)
NCT06977724 · 36 participants (planned) · Start Aug 26, 2025 · Primary completion Mar 2029
Drug: ABBV-319 · For: Dry Eye Syndrome; Systemic Lupus Erythematosus
Sites: Margate, Florida; Tampa, Florida; Orland Park, Illinois · 9 sites in all
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPivotal-lookingRecruiting
NCT06617325 · 450 participants (planned) · Start Nov 21, 2024 · Primary completion May 31, 2028
Drug: DZP · For: Systemic Lupus Erythematosus
Sites: Avondale, Arizona; Chandler, Arizona; Gilbert, Arizona · 247 sites in all
AbbVieAbbVie (ABBV)
NCT07607964 · 30 participants (planned) · Start May 28, 2026 · Primary completion Jan 2029
Drug: ABBV-519; ABBV-519 · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis
Sites: Anniston, Alabama; Tustin, California; Clearwater, Florida · 17 sites in all
- A Study of E6742 in Participants With Systemic Lupus ErythematosusPivotal-lookingRecruiting
Eisai Co., Ltd.Eisai
NCT07515014 · 256 participants (planned) · Start Mar 31, 2026 · Primary completion Aug 5, 2028
Drug: E6742 · For: Systemic Lupus Erythematosus
Sites: Bengbu, China; Beijing, China; Chongqing, China · 63 sites in all
- Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)Pivotal-lookingRecruiting
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
NCT07611747 · 1,117 participants (planned) · Start Apr 22, 2026 · Primary completion Apr 22, 2031
Drug: High-intensity lipid-lowering therapy · For: Rheumatoid Arthritis (RA); Psoriatic Arthritis (PsA); Systemic Lupus Erythematosus (SLE) and 4 more
Sites: Elche, Spain; Orihuela, Spain; Sant Joan d'Alacant, Spain · 17 sites in all
- Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem CellsRecruiting
Shenzhen Beike Bio-Technology Co., Ltd.Industry
NCT07041801 · 58 participants (planned) · Start Feb 15, 2025 · Primary completion Sep 5, 2027
Drug: hUC-MSCs treatment (low dose); hUC-MSCs treatment (medium dose) and 3 more · For: Systemic Lupus Erythematosus (SLE)
Sites: Shenzhen, China
National Cancer Institute (NCI)NIH
NCT03816345 · 300 participants (planned) · Start Jul 16, 2019 · Primary completion Mar 30, 2028
Drug: Cabozantinib; Fluoropyrimidine and 4 more · For: Autoimmune Disease; Crohn Disease; Dermatomyositis and 11 more
Sites: Birmingham, Alabama; Palo Alto, California; Sacramento, California · 52 sites in all
Diabetes Free, Inc.Industry
NCT07946367 · 72 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 2028
Drug: DFI205 bispecific antibody · For: Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Systemic Sclerosis (SSc) and 1 more
Sites: Erlangen, Germany
AstraZenecaAstraZeneca (AZN)
NCT06897930 · 150 participants (planned) · Start Apr 21, 2025 · Primary completion May 1, 2029
Drug: AZD0120; Cyclophosphamide and 1 more · For: Lupus Erythematosus, Systemic
Sites: San Francisco, California; Stanford, California; Tampa, Florida · 20 sites in all
Stephan Grupp MD PhDAcademic, hospital or other
NCT05029336 · 20 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: Depletion of CD3/CD19 in an autologous stem cell transplant · For: Systemic Lupus Erythematosus; Systemic Sclerosis
Sites: Philadelphia, Pennsylvania
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07598396 · 30 participants (planned) · Start May 25, 2026 · Primary completion Aug 11, 2028
Drug: Mosunetuzumab · For: Lupus; Systemic Lupus Erythematosus; Lupus Nephritis
Sites: CABA, Argentina; Buenos Aires, Argentina; Salvador, Brazil · 24 sites in all
- A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07430306 · 245 participants (planned) · Start Apr 13, 2026 · Primary completion Jan 26, 2029
Drug: Anifrolumab · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 108 sites in all
Shanghai Cell Therapy Group Co.,LtdIndustry
NCT07174843 · 20 participants (planned) · Start Sep 9, 2025 · Primary completion Aug 2027
Drug: CD19/CD22/BCMA CAR-T cells(BZE2204) · For: Idiopathic Inflammatory Myopathies(IIM); Immune Thrombocytopenia(ITP); Systemic Lupus Erythematosus(SLE)
Sites: Shanghai, China
- A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Pivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07409181 · 405 participants (planned) · Start Apr 20, 2026 · Primary completion Feb 4, 2029
Drug: BI 3000202; Placebo · For: Systemic Lupus Erythematosus
Sites: Beverly Hills, California; La Palma, California; San Diego, California · 139 sites in all
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07691970 · 1,072 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 30, 2032
Drug: Anifrolumab · For: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 166 sites in all
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07840287 · 404 participants (planned) · Start Oct 22, 2026 · Primary completion Sep 1, 2031
Drug: Enpatoran · For: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Troy, Michigan
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusPivotal-lookingRecruiting
Beeline Medicines CorporationIndustry
NCT07881120 · 390 participants (planned) · Start Nov 3, 2026 · Primary completion Apr 2030
Drug: Afimetoran; Placebo · For: Cutaneous Lupus Erythematosus (CLE); Systematic Lupus Erythematosus
Sites: San Diego, California; DeBary, Florida; Missoula, Montana
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06133972 · 550 participants (planned) · Start May 21, 2024 · Primary completion Apr 3, 2034
Drug: Placebo; Ianalumab · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Burbank, California; La Palma, California · 167 sites in all
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06711887 · 348 participants (planned) · Start May 19, 2025 · Primary completion Aug 1, 2035
Drug: Ianalumab · For: Lupus Nephritis
Sites: Orchard Park, New York; Vitória, Brazil; Salvador, Brazil · 53 sites in all
- Dapagliflozin in Active Lupus NephritisRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT07323524 · 33 participants (planned) · Start May 22, 2026 · Primary completion Jul 1, 2028
Drug: Dapagliflozin (10Mg Tab) along with standard medical therapy; Placebo · For: Lupus Nephritis (LN)
Sites: Boston, Massachusetts · 2 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07629583 · 46 participants (planned) · Start Nov 2, 2026 · Primary completion Mar 29, 2030
Drug: Cevostamab; Tocilizumab · For: Lupus Erythematosus, Systemic
Sites: Parkville, Australia; Porto Alegre, Brazil; Ribeirão Preto, Brazil · 11 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07649265 · 63 participants (planned) · Start Sep 24, 2026 · Primary completion Nov 20, 2028
Drug: HBM7020 · For: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Systemic Sclerosis and 1 more
Sites: Brisbane, Australia
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07355218 · 202 participants (planned) · Start Apr 1, 2026 · Primary completion May 25, 2029
Drug: Enpatoran; Placebo and 1 more · For: Systematic Lupus Erythematosus; Cutaneous Lupus Erythematosus
Sites: Upland, California; DeBary, Florida; Fort Lauderdale, Florida · 70 sites in all
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseasePivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07332481 · 202 participants (planned) · Start Mar 10, 2026 · Primary completion May 24, 2029
Drug: Enpatoran; Placebo and 1 more · For: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Los Angeles, California; Thousand Oaks, California; Cooper City, Florida · 74 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.